We also observed that the three leukemia cell lines showed different responses after CF treatment. In particular, U937 cells seemed to be the most sensitive line upon CF
administration, showing the highest reduction of cell viability as well as the highest caspase-3 activation and GLUT-1 expression decrease, as compared to Jurkat and K562 cells. These findings should be probably due to the different Pictilisib cost metabolic features of the three leukemic lines; in fact, Jurkat cells are an immortalized line of T lymphocytes, while K562 and U937 cells are myelogenous leukemia lines, the first with erythroid features and the second with monocyte properties. Conclusions Modulation of cell signaling, apoptotic pathways and tumor metabolism by dietary agents and nutraceutical compounds may provide MLN8237 new opportunities in both prevention and treatment of cancer. Herein we supply evidence for a significant antiproliferative effect LY2874455 of the nutritional supplement Cellfood™ on leukemia cell lines by inducing cell death through an apoptotic mechanism and by altering cell metabolism through HIF-1α and GLUT-1 regulation. Thanks to its antioxidative and proapoptotic properties,
CF might be a good candidate for cancer prevention. Large-scale clinical trials will be needed to validate the usefulness of this agent either alone or in combination with the existing standard care. References 1. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E: Energy metabolism in tumor cells. FEBS J 2007, 274:1393–1418.PubMedCrossRef 2. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85–95.PubMedCrossRef 3. Kim JW, Dang CV: Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 2006, 66:8927–8930.PubMedCrossRef 4. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB: The biology of cancer: Metabolic reprogramming Methamphetamine fuels cell growth and proliferation. Cell Metab 2008, 7:11–20.PubMedCrossRef 5. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703–707.PubMedCrossRef 6. Jones
RG, Thompson CB: Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009, 23:537–548.PubMedCrossRef 7. Semenza GL: HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010, 20:51–56.PubMedCrossRef 8. Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625–634.PubMedCrossRef 9. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008, 8:705–713.PubMedCrossRef 10. Yeung S, Pan J, Lee MH: Roles of p53, Myc and HIF-1 in regulating glycolysis – the seventh hallmark of cancer. Cell Mol Life Sci 2008, 65:3981–3999.PubMedCrossRef 11. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495–516.PubMedCrossRef 12. Wong RS: Apoptosis in cancer: from pathogenesis to treatment.